Sale

Science Business: The Promise, the Reality, and the Future of Biotech

Regular price RM70.50 MYR Now RM55.58 MYR Save 21%
Unit price
per
Compare to estimated retail price: RM155.52 MYR  

Biotech industry's promises versus actual performance.

If you're intrigued by the intersecting paths of science and commerce, "Science Business" offers a compelling examination. Gary P. Pisano delves into why biotech hasn't lived up to its hype, making it a thought-provoking read for anyone interested in the future of this high-stakes sector. It's an insightful critique with constructive solutions that should interest professionals and enthusiasts keen on understanding the industry's dynamics.

Note: While we do our best to ensure the accuracy of cover images, ISBNs may at times be reused for different editions of the same title which may hence appear as a different cover.
Sale

Science Business: The Promise, the Reality, and the Future of Biotech

Regular price RM70.50 MYR Now RM55.58 MYR Save 21%
Unit price
per
Compare to estimated retail price: RM155.52 MYR  
ISBN: 9781591398400
Authors: Gary P. Pisano
Date of Publication: 2006-11-14
Format: Hardcover
Related Collections: Business, Science, Economics
Related Topics: Technology, Biology, Health
Goodreads rating: 3.71
(rated by 107 readers)

Description

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech's problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policy makers seeking ways to improve the industry's performance. According to Pisano, the biotech industry's problems stem from its special character as a science-based business. This character poses three unique challenges: how to finance highly risky investments under profound uncertainty and long time horizons for R&D, how to learn rapidly enough to keep pace with advances in drug science knowledge, and how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases. The key to fixing the industry? Business models, organizational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter-term 'monetization' of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care, and a shinier future for human well-being.
Condition guide
 

Similar Reads

Biotech industry's promises versus actual performance.

If you're intrigued by the intersecting paths of science and commerce, "Science Business" offers a compelling examination. Gary P. Pisano delves into why biotech hasn't lived up to its hype, making it a thought-provoking read for anyone interested in the future of this high-stakes sector. It's an insightful critique with constructive solutions that should interest professionals and enthusiasts keen on understanding the industry's dynamics.

Note: While we do our best to ensure the accuracy of cover images, ISBNs may at times be reused for different editions of the same title which may hence appear as a different cover.